Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing…
2015/04/22 – 2014 Annual financial report now available – Update on Q1 2015 activity
Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing…
2015/04/15 – Quantum Genomics to meet investors at the European Smallcap Event, April 27 & 28, 2015
Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing…
2015/03/17 – Creation of a joint Inserm-Quantum Genomics laboratory at the Collège de France backed by the French National Agency for Research (ANR)
Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing…
2015/03/03 : First patients recruited for Phase IIa trial of drug candidate QGC001
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Quantum Genomics reports total capital increase after stabilization period: €12.9 million
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
Remarkable uptake in Quantum Genomics IPO:1 €11.2 million raised
Quantum Genomics (Alternext – FR0011648971 – ALQGC) announces the great success of its Initial Public…
Quantum Genomics is launching a public equity offering on Alternext Paris, above all to fund the phase IIa clinical trials of its antihypertensive drug candidate QGC001
Quantum Genomics (Alternext – FR0011648971 – ALQGC) announces the launch of a public equity offering…
2015/01/12 – Quantum Genomics at J.P. Morgan 34th annual healthcare conference
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…